ResearcherJiangsu Province HospitalNo recent work listed

Dalai Xu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5026225175. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper

Papers 3

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2022.726985 ↗
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Co-author DOI 10.1016/j.biopha.2019.109521 ↗
EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Co-author DOI 10.1016/j.biopha.2020.109972 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Feng Zhu · 2 shared papers, 2020 · strength 0.22
- Paper EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathw… DOI 10.1016/j.biopha.2020.109972 ↗
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Yi Miao · 2 shared papers, 2020 · strength 0.22
- Paper EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathw… DOI 10.1016/j.biopha.2020.109972 ↗
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Junli Wu · 2 shared papers, 2020 · strength 0.22
- Paper EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathw… DOI 10.1016/j.biopha.2020.109972 ↗
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Shangnan Dai · 2 shared papers, 2020 · strength 0.22
- Paper EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathw… DOI 10.1016/j.biopha.2020.109972 ↗
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Xue-Ang Liu · 1 shared paper, 2022 · strength 0.15
- Paper A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. DOI 10.3389/fonc.2022.726985 ↗
Yi Zhu · 1 shared paper, 2022 · strength 0.15
- Paper A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. DOI 10.3389/fonc.2022.726985 ↗
Xiaole Zhu · 1 shared paper, 2020 · strength 0.10
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Yunpeng Peng · 1 shared paper, 2020 · strength 0.10
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Yi Zhu · 1 shared paper, 2020 · strength 0.10
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗
Qiuyang Chen · 1 shared paper, 2020 · strength 0.10
- Paper Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. DOI 10.1016/j.biopha.2019.109521 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.